Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis

Cancer

Volumn 113, Issue 3, 2008, Pages 530-541

  Ishikawa, Keidai ^a   Miyamoto, Masaki ^a   Yoshioka, Tatsuya ^a   Kato, Tatsuya ^b   Kaji, Mitsuhito ^b   Ohbuchi, Toshiro ^c   Hirano, Satoshi ^a   Itoh, Tomoo ^d   Dosaka Akita, Hirotoshi ^a   Kondo, Satoshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sapporo Minami Sanjo Hospital   (Japan)

^c Minami ichijo Hospital   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

CD154; CD40; Immunohistochemistry; Juxtacrine; Lung cancer

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD40; CARCINOMA, NON-SMALL-CELL LUNG; CD40 LIGAND; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; MIDDLE AGED; PARACRINE COMMUNICATION; PROGNOSIS; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 49049096326     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23618     Document Type: Article

References (22)

1. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995:a report card for the U.S. Cancer. 1998;82:1197-1207.
2. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg. 2001;71:1759-1764.
3. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922.
4. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlman B. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother. 1985;20:23-28.
5. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263-1272.
6. Zong YS, Lin H, Choy DTK, et al. Nasopharyngeal carcinoma and lymphoinfiltration. Oncology. 1991;48:290-296.
7. Armitage RJ, Fanslow WC, Stockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature. 1992;357:80-82.
8. Banchereau J, De Paoli P, Valle A, et al. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science. 1991;251:70-72.
9. Van den Oord JJ, Maes A, Stas M, et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol. 1996;149:1953-1961.
10. Costello A, Rey-Hipolito C, Patel A, et al. Thyroid cancers express CD-40 and CD-40 ligand: cancers that express CD-40 ligand may have a greater risk of recurrence in young patients. Thyroid. 2005;2:105-113.
11. Sabel MS, Yamada M, Kawaguchi Y, et al. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother. 2000;49:101-108.
12. Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001;3:691-703.
13. Yamada M, Shiroko T, Kawaguchi Y, et al. CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human nonsmall cell lung tumors. Int J Cancer. 2001;92:589-599.
14. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors, 6th ed. New York, NY: John Wiley & Sons; 2002.
15. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494.
16. Cho Y, Miyamoto M, Kato K, et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 2003;63:1555-1559.
17. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA. 1997;94:599-603.
18. Higashiyama S, Iwamoto R, Goishi K, et al. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol. 1995;128:929-938.
19. Eriksson T, Frisk T, Gray SG, et al. Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma. Exp Cell Res. 2001;270:88-95.
20. Hellings PW, Kasran A, Bullens D, et al. IL-10- and IL-12-independent down-regulation of allergic sensitization by stimulation of CD40 signaling. J Immunol. 2006;177:5138-5144.
21. Toyooka S, Tokumo M, Shigematsu H, et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res. 2006;66:1371-1375.
22. Chiodoni C, Iezzi M, Guiducci C, et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med. 2006;203:2441-2450.